The U.S. diabetic retinopathy market is projected to grow from USD 3.44 billion in 2025 to around USD 5.93 billion by 2035, expanding at a CAGR of 5.60%. Growth is driven by the rising prevalence of diabetes, increasing awareness of early eye disease diagnosis, and advancements in retinal treatment technologies.

U.S. Diabetic Retinopathy Market Statical Scope

According to research estimates, the rural areas in the USA represent a smaller number of ophthalmologists, and countries in the Southern USA hold the lowest number of eye care providers per capita. The U.S. witnesses an urgent need for providing optical care to diabetic patients, while prioritising the screening of diabetic retinopathy. The future interventions, such as teleretinal screening and telemedicine , will allow more patients to receive early intervention and screening for diabetic retinopathy in rural areas to improve long-term outcomes.

U.S. Diabetic Retinopathy Market Share, By Type, 2025 (%)

• Non-proliferative Diabetic Retinopathy (NPDR)- The non-proliferative diabetic retinopathy segment held a major revenue share of 70.50%, owing to the use of Optical Coherence Tomography (OCT) and comprehensive dilated eye exams to diagnose diabetic macular edema.
• Proliferative Diabetic Retinopathy (PDR)- The proliferative diabetic retinopathy segment led with a share of 29.50%, due to the growing focus on strict control of blood sugar, cholesterol, and blood pressure with regular dilated eye exams to detect changes early.

U.S. Diabetic Retinopathy Market Share, By Management, 2025 (%)

• Anti-VEGF- The anti-VEGF segment drove the market with a share of 56.50%, driven by the potential of these intravitreal injections to prevent abnormal vessel growth, reduce retinal vascular leakage, and improve vision.
• Intraocular Steroid Injection- The intraocular steroid injection segment accelerated the market with a share of 17.50%, led by its primary uses in patients who have had cataract surgery and who cannot receive frequent anti-VEGF injections.
• Laser Surgery- The laser surgery segment surged with a share of 14.00%, supported by its high effectiveness in preventing severe vision loss and macular edema.

Top Companies in the U.S. Diabetic Retinopathy Market

• Bayer AG
• AbbVie Inc.
• Novartis AG
• Oxurion NV.
• Sirnaomics
• Alimera Sciences
• Ampio Pharmaceuticals Inc.
• BCNPeptides
• Kowa Company, Ltd.
• Genentech, Inc.

Segments Covered in the Report

By Type

• Proliferative Diabetic Retinopathy
• Non-proliferative Diabetic Retinopathy

By Management

• Anti-VEGF
• Intraocular Steroid Injection
• Laser Surgery
• Vitrectomy